IGF1 and neoplasm: Although MK-0646 was the only treatment that failed to inhibit in vivo tumor growth, antibody efficacy was first confirmed as ‘IGF-1 Signaling’ was predicted as a significantly inhibited pathway in the MK-0646 cohort.